Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis

Integrin alpha-4 (ITGA4) is a validated therapeutic target for multiple sclerosis (MS) and Natalizumab, an antibody targeting ITGA4 is currently approved for treating MS. However, there are severe side effects related to this therapy. In this study, we report the development of a novel DNAzyme that...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakravarthy, Madhuri, Aung-Htut, May T., Le, Bao T., Veedu, Rakesh N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431638/
https://www.ncbi.nlm.nih.gov/pubmed/28487530
http://dx.doi.org/10.1038/s41598-017-01559-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431638/
https://www.ncbi.nlm.nih.gov/pubmed/28487530
http://dx.doi.org/10.1038/s41598-017-01559-w

Ejemplares similares